• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Little William Reed bought $28,000 worth of shares (4,000 units at $7.00), increasing direct ownership by 1% to 307,859 units (SEC Form 4)

    6/3/24 4:15:30 PM ET
    $OBIO
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $OBIO alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Little William Reed

    (Last) (First) (Middle)
    C/O ORCHESTRA BIOMED HOLDINGS, INC.
    150 UNION SQUARE DRIVE

    (Street)
    NEW HOPE PA 18938

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Orchestra BioMed Holdings, Inc. [ OBIO ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    05/30/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.0001 per share ("Common Stock") 05/30/2024 P 4,000 A $7 307,859(1) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Includes 303,859 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock, subject to applicable vesting schedules and conditions.
    Remarks:
    Executive Vice President, Corporate Development & Strategy
    /s/ Matthew R. Schob, Attorney-in-Fact 06/03/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $OBIO

    DatePrice TargetRatingAnalyst
    3/20/2025$12.00Buy
    BTIG Research
    1/2/2025$16.00Overweight
    Barclays
    8/22/2024$14.00Buy
    H.C. Wainwright
    7/25/2024$15.00Buy
    B. Riley Securities
    1/19/2024$14.00Buy
    Jefferies
    2/24/2023$15.00Overweight
    Piper Sandler
    2/7/2023$20.00Buy
    Chardan Capital Markets
    More analyst ratings

    $OBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Orchestra BioMed with a new price target

      BTIG Research initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $12.00

      3/20/25 8:00:48 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Barclays initiated coverage on Orchestra BioMed with a new price target

      Barclays initiated coverage of Orchestra BioMed with a rating of Overweight and set a new price target of $16.00

      1/2/25 8:04:57 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • H.C. Wainwright initiated coverage on Orchestra BioMed with a new price target

      H.C. Wainwright initiated coverage of Orchestra BioMed with a rating of Buy and set a new price target of $14.00

      8/22/24 7:33:07 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Rtw Investments, Lp bought $149,201 worth of shares (49,900 units at $2.99) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      5/1/25 8:18:11 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Large owner Rtw Investments, Lp bought $126,500 worth of shares (50,000 units at $2.53) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      4/29/25 5:16:34 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Officer Hochman David P bought $18,640 worth of shares (4,000 units at $4.66), increasing direct ownership by 0.70% to 579,498 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      12/26/24 5:46:42 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    SEC Filings

    See more
    • SEC Form 144 filed by Orchestra BioMed Holdings Inc.

      144 - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      6/26/25 3:11:30 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      6/24/25 4:14:38 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Orchestra BioMed Holdings Inc.

      10-Q - Orchestra BioMed Holdings, Inc. (0001814114) (Filer)

      5/12/25 4:05:52 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

      Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures. The submission builds upon the successful results of the PATCH study as well as positive clinical use in Europe, reinforcing the system's potential safety and performance profile. In addition, the company received European CE mark approval for an expanded indication for PerQseal Elite

      6/24/25 8:00:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

      Presentation underscores unique potential for atrioventricular interval modulation ("AVIM") therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction and progression to heart failure with preserved ejection fraction ("HFpEF")Hypertensive heart disease represents over 7.7 million U.S. patients, the same population with hypertension and elevated cardiovascular risk cited in the recent FDA Breakthrough Device Designation ("BDD") for AVIM therapy NEW HOPE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to pat

      6/18/25 9:30:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

      FDA Breakthrough Device Designation Awarded to AVIM Therapy FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch NEW HOPE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline. Q1 2025 Highlights: U.S. Food and Drug Administration ("FDA") Breakthrough Device Design

      5/12/25 4:28:21 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $OBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Fain Eric S sold $8,183 worth of shares (2,683 units at $3.05) (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      6/27/25 5:10:00 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Aryeh Jason was granted 12,422 shares, increasing direct ownership by 16% to 92,482 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      6/27/25 5:09:09 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Cleary Chris was granted 12,422 shares, increasing direct ownership by 122% to 22,577 units (SEC Form 4)

      4 - Orchestra BioMed Holdings, Inc. (0001814114) (Issuer)

      6/26/25 5:20:24 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

      NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

      3/31/25 4:21:30 PM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products
    • Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

      The BACKBEAT global pivotal study is currently enrolling patients to evaluate the efficacy and safety of atrioventricular interval modulation ("AVIM") therapy for patients who have uncontrolled hypertension and a pacemaker indicationA globally recognized thought leader and innovator in cardiovascular technologies, including electrophysiology and cardiac rhythm management, Dr. Reddy currently serves as the Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital, the Director of Electrophysiology for the Mount Sinai Health System, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine a

      2/18/25 8:00:00 AM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

      Medical device industry veteran brings over three decades of expertise in M&A, as well as structured research and development ("R&D") collaborations aligned with Orchestra BioMed's partnership-enabled business model Mr. Cleary previously served as Senior Vice President ("SVP") of Corporate Development at Medtronic plc (NYSE:MDT) ("Medtronic"), where he played a key role in establishing the strategic collaboration between Orchestra BioMed and Medtronic for atrioventricular interval modulation ("AVIM") therapy in hypertension with increased cardiovascular riskEric A. Rose, M.D. to transition from Board Member to Board Member Emeritus and Strategic Advisor, continuing to provide invaluable expe

      2/5/25 8:00:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products

    $OBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:19:57 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Orchestra BioMed Holdings Inc.

      SC 13D/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      8/7/24 5:16:55 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Orchestra BioMed Holdings Inc.

      SC 13G/A - Orchestra BioMed Holdings, Inc. (0001814114) (Subject)

      7/17/24 4:32:50 PM ET
      $OBIO
      Medicinal Chemicals and Botanical Products
      Health Care

    $OBIO
    Financials

    Live finance-specific insights

    See more
    • Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

      Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an exclusive strategic collaboration for global development and commercialization of BackBeat Cardiac Neuromodulation Therapy™ (CNT), now also known as Atrioventricular Interval Modulation ("AVIM") therapy, for hypertensive pacemaker patientsBACKBEAT global pivotal study is expected to start before the end of 2023 IDE supported by data from the MODERATO II randomized pilot study that showed AVIM therapy drove significant and sustained reductions in blood pressure in hypertensive pacemaker patients Orc

      9/19/23 7:30:00 AM ET
      $MDT
      $OBIO
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medicinal Chemicals and Botanical Products